The boundary between biology and engineering has effectively dissolved, allowing scientists to reprogram human immune cells to target cancer with surgical precision. This shift from toxic chemotherapy to 'living medicines' like CAR T-cells and CRISPR-edited lymphocytes is transforming terminal diagnoses into stories of survival. While the promise of curing autoimmunity and solid tumors is closer than ever, the move toward editing human embryos raises profound ethical questions about the loss of human diversity and the risks of genetic fads.